

NUTRITIONAL GROWTH SOLUTIONS RAISES \$3.48 MILLION TO DRIVE GROWTH FOLLOWING LAUNCH INTO WALMART STORES

HIGHLIGHTS:

- Firm commitments received to raise A\$3.48 million via a Placement (before costs) at 12 cents per share, which includes 1 free option for every 2 shares subscribed for
- Strong support from new and existing sophisticated and institutional investors in Australia
- Capital raised will provide funding to grow sales at Walmart, through additional purchase orders and specific marketing campaigns
- It will also accelerate sales with other key retailers across North America and South East Asia

22 August 2022: Nutritional Growth Solutions Ltd. (“the Company” or “NGS”, ASX:NGS), a global nutrition company that creates premium quality nutrition products for children worldwide, has secured A\$3.48 million (before costs) at 12 cents per share through a share placement (**Placement**) to new and existing institutional and sophisticated investors.

The Placement follows the recently expanded agreement with Walmart, which will see NGS supply its Healthy Heights® product range to 403 bricks and mortar Walmart stores across the United States, a transformational development for the Company.

Placement proceeds will be used to fund future purchase orders with Walmart and rollout marketing campaigns to Walmart customers. In addition, the funds will help to accelerate sales with other key retailers across North America and South East Asia.

Nutritional Growth Solutions CEO and Managing Director, Liron Fendell said:

“We are very excited to have secured funding to help accelerate NGS’ global rollout. We are encouraged by the strong level of support shown by new and existing investors to build the Healthy Heights® portfolio into a global household name. The Walmart agreement represents a substantial opportunity for us, both in terms of growing sales and also building our brand awareness in the large and lucrative US market.

“The Walmart agreement is just the first step in our physical store rollout, with the potential to expand our sales program beyond the initial 403 Walmart stores into Walmart’s broader store network, as well as the potential for agreements with other major retailers.

“There has been really strong momentum over the past few months, signing sales agreements with key retailers across North America and Asia. This Placement now enables us to accelerate our sales into these



retailers to drive strong revenue growth, as well as continuing to expand our product range and enter new markets.

“I would like to thank all existing shareholders for their continued support and welcome new shareholders at this very exciting time of growth for the Company.”

Placement Details

The Placement comprises an offer of 29,000,000 new fully paid ordinary shares in the Company (**Placement Shares**) at an issue price of A\$0.12 per share (**Offer Price**), raising a total A\$3.48 million. The issue price of A\$0.12 per share represents the last closing share price on 18 August 2022. The Placement Shares will be issued under the Company’s existing 7.1 and 7.1A capacities.

The Placement includes 1 free listed option (**Options**) for every 2 Placement Shares subscribed for. The Options are exercisable at A\$0.27 cents per share with an expiry of 19 November 2023 and currently trade under the code ASX:NGSO. The issue of the Options will be subject to shareholder approval.

Related parties of NGS have committed to subscribe for \$50,000 (416,666 Placement Shares), which will also be subject to shareholder approval.

Molo Capital Limited (**Molo Capital**) acted as Lead Manager to the Capital Raising. Details of Molo Capital’s fees are included in the Appendix 3B released at the same time as this announcement and include, as part consideration, the issue of Options which will also be subject to shareholder approval.

Use of funds

Proceeds from the Placement will support:

- Sales and marketing efforts in North America
- Sales and marketing efforts in South East Asia
- Research and development as part of clinical trials and new product development
- Working capital & inventory to support supply of product into retail expansion

This announcement has been authorised for release by the CEO and Chairman of the Board of Nutritional Growth Solutions Ltd.

-ends-



For more information:

Liron Fendell, CEO & MD
Nutritional Growth Solutions Ltd.
E: liron@ngsolutions.co

Investors

Eric Kuret
Automic Group
P: +61 417 311 335
E: eric.kuret@automicgroup.com.au

Media

Tristan Everett
Automic Group
P: +61 403 789 096
E: tristan.everett@automicgroup.com.au

About Nutritional Growth Solutions

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children's Medical Centre, Israel's largest pediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

ngsolutions.co